Prediction meets causal inference: the role of treatment in clinical
  prediction models by van Geloven, Nan et al.
ar
X
iv
:2
00
4.
06
99
8v
1 
 [s
tat
.M
E]
  1
5 A
pr
 20
20
Prediction meets causal inference: the role of
treatment in clinical prediction models
N van Geloven1∗, SA Swanson2, CL Ramspek3, K Luijken3,
M van Diepen3, TP Morris4, RHH Groenwold1,3,
HC van Houwelingen1, H Putter1, S Le Cessie1,3
April 16, 2020
Abstract
In this paper we study approaches for dealing with treatment when devel-
oping a clinical prediction model. Analogous to the estimand framework
recently proposed by the European Medicines Agency for clinical trials, we
propose a ‘predictimand’ framework of different questions that may be of
interest when predicting risk in relation to treatment started after baseline.
We provide a formal definition of the estimands matching these questions,
give examples of settings in which each is useful and discuss appropriate
estimators including their assumptions. We illustrate the impact of the pre-
dictimand choice in a dataset of patients with end-stage kidney disease. We
argue that clearly defining the estimand is equally important in prediction
research as in causal inference.
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1 Introduction
Clinical prediction models provide individualized prognostic information that
can be used to counsel patients about the likely course of their disease. Pre-
diction models can also support treatment decisions. For instance, if a pa-
tient’s risk of a poor outcome in the next year is relatively low, then she or
he may not need treatment. If the risk of a poor outcome is high, additional
preventive or curative treatments should be considered [1]. But what is ex-
actly meant by “a patient’s prognosis” or “a patient’s risk” here? Do we
mean the risk assuming that no treatment is given, the risk under current
standard treatment, the risk of experiencing the event in the time period
before being treated, or something else? An increasing number of clinical
prediction models are becoming available through websites and apps. How-
ever, for many of these models it is unclear how the risk they aim to capture
relates to treatment.
The data sources used for the development of clinical prediction models
often contain data on a mix of patients who did and did not receive treat-
ments that affect the risk of the event of interest. This holds both for ob-
servationally collected data and for trial data. Completely untreated cohorts
can sometimes be found in historical data collections, but these cohorts are
rare and may not be relevant to current practice in other important ways.
Using data solely from untreated patients can also lead to highly selected
cohorts that are not generalizable. Dealing with treated patients is thus a
challenge that needs to be addressed when developing a clinical prediction
model. Baseline treatments can be included as predictors when developing,
or externally validating, a prediction model, meaning that for a new patient
the model can be used to predict the outcome, provided information is avail-
able about baseline treatment status and other predictors [2]. However, for
treatments that are initiated after baseline, there is no easy solution, nor is
there a single question of interest [3]. We do not know at baseline what treat-
ments will be initiated later on and we cannot use future values as predictors.
Moreover, the way treatments are dealt with during model development will
have impact on how predictions can be used in future patients. Currently,
ad hoc approaches are used where treatment initiation may be ignored, pa-
tients are censored at the moment they start or switch treatment, or even
excluded completely from the development cohort. Such analysis choices
are often reported as mere technical analysis issues [4], but they may have
a major impact on interpretation. The predictions resulting from such ap-
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proaches might end up targeting a different risk than researchers intended.
For example, censoring patients when they receive a transplantation when
estimating survival among patients listed for liver transplantation has shown
to overestimate the actual observed waiting list mortality [5, 6]. The TRI-
POD reporting guideline on development and validation of prediction models
offers hardly advice on the issue. The only related point on the TRIPOD
checklist is that one should describe the treatments that patients received, if
relevant (item 5c) [7].
The European Medicines Agency (EMA) has recently released a new
guideline that provides a framework to deal with additional treatments started
after baseline and other so-called intercurrent (post-baseline but pre-outcome)
events in the context of clinical trials: the addendum to the ICH E9 guideline
Statistical Principles for Clinical Trials [8]. The guideline distinguishes five
possible strategies: a ‘treatment policy’ strategy that follows the intention-
to-treat principle and ignores any change in treatment after baseline, a ‘com-
posite’ strategy that includes the start of an additional treatment as part
of the outcome definition, a ‘hypothetical’ strategy that aims to assess the
outcome in a scenario where no additional treatment would be given, a ‘prin-
cipal stratum’ strategy where the outcome is considered in a certain subset of
patients who would never start the additional treatment independent of their
allocated treatment, and a ‘while on treatment’ strategy where the outcome
is assessed in the time period up until the additional treatment is started. To-
gether with the definition of the population, the outcome of interest and the
effect measure, each strategy defines an estimand which is the target quantity
that the trialists aim to estimate. Each estimand represents a different causal
question. In the trial context, these questions relate to treatment effects. In
prediction models, the aim is to assess patients’ expected outcomes condi-
tional on certain patient characteristics measured at baseline. We argue that,
just like in trials, the quantity that a clinical prediction model targets should
be unequivocally defined. Therefore we map the E9 estimand framework to
the context of prediction models, proposing a predictimand framework.
Our focus in this manuscript is on prognosis over time, so on time-to-event
or failure-time outcomes. We consider treatments that are initiated during
follow-up. Previous studies on estimands in prediction research considered
point (time-invariant) treatments [2] and binary outcomes [3]. Recently, Pa-
jouheshnia and colleagues discussed analysis methods for time-to-event pre-
diction of untreated risk in the presence of time-dependent treatment [9].
Here we will extend that work by considering different questions that can
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be assessed by prediction models and that will be of interest in different ap-
plied settings. We formulate these strategies analogous to the trial estimand
framework from the E9 addendum. We provide a formal definition of the
prediction estimands matching these questions. For each of the estimands,
we discuss key assumptions for estimation and list common estimators. We
illustrate the impact of the predictimand choice in a dataset of patients with
end-stage kidney disease.
2 Notation
To simplify, we consider only one treatment (A) that is related to the event
of interest. Patients are all event-free and without this treatment at time
zero. At that moment we collect baseline covariates X(0), which will be
used to determine the prognosis of the patient. T is the time to the event
of interest. Some patients will start treatment A over time, with V the
time to treatment start and A(t) the time dependent treatment indicator.
In principle, A(t) could switch between 0 (no treatment) and 1 (treatment)
multiple times over the follow up, but, to enhance readability, in the following
we will assume that once patients initiated treatment, they stay in the treated
condition throughout. For patients who experience the event of interest
before treatment start, V is latent. Both T and V can be censored by end
of study or loss to follow up which we assume for simplicity to be non-
informative censoring mechanisms. In some studies, patients are no longer
followed for the event of interest after treatment initiation, for instance in a
registry of patients on dialysis that no longer follows patients after a kidney
transplantation. This situation is depicted in Figure 1a. If follow up on
the event of interest does continue after a new treatment is initiated, we
are in the setting depicted in Figure 1b. The two figures are not causal
directed acyclic graphs, but could be viewed as state transition diagrams of
a multistate model [10]. Figure 1a is similar to a competing risks setting and
Figure 1b is similar to that of an illness death model, with the intermediate
state in our case not disease but treatment. The pace at which patients
initiate treatment is denoted by the transition intensity α(t, Ht), where Ht
is the history of the patient up to time point t. Later on, we will distinguish
between situations where the treatment decisions are only based on patients’
baseline prognostic covariates, i.e., Ht = {X(0)} and situations where the
treatment decisions are also based on prognostic markers that evolve over
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Figure 1: Graphical representation of the studied situation. Follow up on
the event of interest may stop (panel a) or continue (panel b) after treatment
initiation.
time, i.e., Ht = {X(s); s ≤ t}.
3 Predictimands
Below we describe four strategies for how to deal with treatment initiation
after baseline in the development of a prediction model. We formulate the
interpretation of the resulting prediction estimands, give examples of settings
where they are useful and discuss how they apply to new patients that were
not used for development of the predictions, i.e., their generalizability [11].
The four strategies described have analogous estimands in the E9 addendum.
The fifth -principle stratum- estimand described in the addendum was not
mapped to the prediction setting as it refers to a counterfactual subpopula-
tion that has no immediate analogue to the prediction setting. In Section 4
we focus on assumptions needed for estimation of the predictimands and list
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some common estimators. An overview is presented in Table 1.
3.1 “Ignore treatment” strategy
In this strategy, treatment initiation is considered part of standard practice.
The value for T , the time to event of interest, is used regardless of whether
patients start treatment or not. So V , the time to treatment, is not used
in any way. This is analogous to the “treatment policy” strategy in the E9
guideline [8]. It has also been described as “simply ignore treatment” [2].
The risk that is estimated equals:
P (T ≤ thor|X(0)), (1)
i.e., the risk of the event of interest occurring before a time horizon thor under
the treatment practice inherent to the development dataset. An example
of where this strategy was used, is in the development of QRISK3, a risk
prediction algorithm that targets a person’s risk of a heart attack or stroke
over the next 10 years [12]. The algorithm was developed using individuals
who did not use statins at baseline, but statin use after baseline was ignored,
as discussed in [3]. The calculated risks therefore belong to a population
where some individuals will receive statins during follow up. The algorithm
will only be generalizable to new patient groups if in those groups the same
treatment assignment policy is used as in the development cohort. This
implies that for all subgroups defined by the predictors in the prediction
model, a similar proportion of patients should initiate treatment as in the
development set. Provided the treatment is effective in reducing the risk of
the outcome, the risk calculated with the “ignore treatment” strategy will
be lower than the untreated risk, that is, the risk for a patient who will not
be treated during follow-up. If the ignore treatment predictimand is falsely
interpreted as untreated risk and used for future decisions on prescribing
(statins), it will underestimate the true untreated risk and this could lead
to undertreatment in new patients [13]. The “ignore treatment” strategy
requires continued follow up after treatment initiation, so it cannot be used
in the study design depicted in Figure 1a.
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Table 1: Overview of the four strategies of dealing with treatment initation after baseline. T time to event
of interest; V time to start of treatment; PCI percutaneous coronary intervention; CABG coronary artery
bypass grafting; IVF in vitro fertilization.
Strategy Estimand Example Estimators Key assumptions
ignore treatment risk of the event,
regardless of treat-
ment
risk of cardiovascular
events where some pa-
tients will initiate statins
according to routine-
care prescriptions
survival model for T , do
not censor at V
treatment assign-
ment policy in
application set-
ting similar to
development data
composite risk of the event or
treatment initiation
risk of a composite of
cardiovascular death,
myocardial infarction
and treatment with
revascularisation (PCI
or CABG)
survival model for
min(T, V )
treatment assign-
ment policy in
application set-
ting similar to
development data
while untreated risk of the event oc-
curring before treat-
ment is started
risk of dying while on
the waiting list for a liver
transplant
competing risks methods treatment assign-
ment policy in
application set-
ting similar to
development data
hypothetical risk of the event
if treatment were
never started
risk of a natural preg-
nancy without IVF
treatment
survival model for T ,
censor at V or include
treatment as time-
dependent covariate in
the model and set to 0
when predicting
exchangeability,
consistency and
positivity
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3.2 “Composite” strategy
In the second strategy, treatment is combined into a composite outcome
together with the event of interest. In such a “composite” strategy we target
P (min(T, V ) ≤ thor|X(0)), (2)
i.e., the risk of the event of interest or the treatment occurring before time
thor. In this strategy the treatment is integrated in the clinical outcome.
An example is predicting the composite of cardiovascular death, myocardial
infarction and treatment with revascularisation (PCI or surgery) [14]. In-
cluding the treatment in the outcome may seem a somewhat artificial way of
dealing with treatment and may lead to a less well interpretable outcome, but
some use cases exist. A “composite” strategy can for instance be used when
the treatment has very likely prevented an imminent occurrence of the event
of interest and treatment can be viewed as a proxy of the event (i.e., with-
out PCI or surgery a patient would develop a myocardial infarction). Other
settings where a composite outcome can be useful is when a poor outcome
is more clearly captured by its consequence of needing treatment than by
giving a precise description of poor health status. For example, Von Dadel-
szen et al. used a composite outcome including amongst others receiving
infusion of a third parental hypertensive drug, intubation, transfusion with
any blood product and dialysis, when predicting severe maternal outcomes
in pre-eclampsia [15]. A third use case for the composite strategy is predict-
ing the chances of a good outcome (one minus composite) defined as staying
event-free without requiring additional treatment. The “composite” strat-
egy does not need continued follow up after treatment initiation. Applying
a composite prediction estimand to new patients requires similar treatment
assignment policies as in the development cohort. For instance, if in the new
setting where the predictions are applied, patients in a certain subgroup are
treated more often than similar patients in the development cohort, then the
predictions of the combined outcome will be lower than the true probabilities
in that subgroup (miscalibration).
3.3 “While untreated” strategy
In the “while untreated” strategy, we are only interested in the event of
interest if it happens before treatment is started. Events occurring after
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treatment start do not count as events. We target the risk of the event of
interest occurring before time thor and before treatment is started.
P (T ≤ thor, T < V |X(0)). (3)
This prediction estimand is well-known from competing risks analysis. It is
often referred to as cumulative incidence. Starting treatment is then con-
sidered a competing event that precludes observing the untreated event of
interest. Cumulative incidence has also been referred to as the absolute risk,
actual risk, crude probability, crude cumulative incidence function, absolute
cause-specific risk or subdistribution function [16, 18, 19]. It has recently
been conceptualized as the “risk without elimination of competing events”
[17]. The analogous name for this strategy in the E9 addendum is “while on
treatment”, referring to the response of the patient during the period where
patients are still on their originally assigned treatment. Note that what dis-
tinguishes this strategy from the “ignore treatment” strategy is that at the
moment treatment is started, the event of interest will by definition not occur
anymore. An example is estimating the risk of dying while on the waiting
list for a liver transplant [5]. Typically this strategy will be of interest if the
treatment is not freely available, but limited due to waiting lists or other
logistical constraints. Also for this strategy, predictions on new patients are
only well calibrated if the assignment policy of treatment is similar to the
development cohort. If in the application setting a subgroup is treated more
often or sooner than in the development set, the predictions will overestimate
the true “while untreated” risk in this subgroup.
3.4 “Hypothetical” strategy
In this strategy we envision a world where treatment does not exist. We aim
to estimate the untreated risk before time thor:
P (T v=∞ ≤ thor|X(0)), (4)
where T v=∞ represents the counterfactual time to the event of interest if V is
set to infinity, i.e., in a hypothetical world where treatment A is eliminated.
Like the “while untreated” strategy, this strategy too has an analogue in the
competing risk literature. Young et al refer to this risk as the “risk under
elimination of competing events” [17]. It has been referred to as the marginal
cumulative incidence, net risk, or pure risk [18, 19]. The risk quantifies how
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likely the event of interest would be if nobody were to receive treatment.
Since we are only interested in the risk up to thor, we could similarly have
used T v>thor instead of T v=∞. In the E9 addendum this strategy is similarly
referred to as the “hypothetical” strategy.
An example application is estimation of the risk of a natural pregnancy
without use of assisted reproductive techniques such as IVF [20]. Other hy-
pothetical scenarios (e.g., what if treatment is started after one year) could
in principle also be targeted. In fact, if we could set v exactly according
to the function that clinicians used in the development cohort to determine
when to start treatment, this estimand would reduce to the “ignore treat-
ment” estimand in (1). But here we only discuss the hypothetical untreated
risk further. Estimating the hypothetical untreated risk is challenging (see
Section 4.4), but, once constructed, it is readily generalisable to new pa-
tients when posing the question what would happen if the new patient is
never treated. This untreated/baseline risk is useful to inform decisions on
treatment A. Note that the three other strategies (ignore treatment, com-
posite and while untreated) cannot be used to inform the decision to start
treatment A, as this might lead to something that has been described as
the ‘prediction paradox’: predictions influencing behaviours (i.e., treatment
decisions) that in turn invalidate predictions [13]. These three predictimands
will be miscalibrated if the treatment decisions made in new patients differ
from those in the development cohort.
4 Estimators and their assumptions
In this section we focus on key assumptions and design elements that are
necessary for estimating each predictimand. Without being exhaustive, we
link the estimands to common estimators.
4.1 “Ignore treatment” strategy
Since in this strategy starting treatment after baseline is ignored, standard
time to event regression methods may be used to relate the event of interest
to the covariates X(0). For instance, one could use Cox regression models
combined with the nonparametric Breslow (or Efron) estimator for the base-
line hazard or flexible parametric survival models. The main assumption
here is that of non-informative censoring for reasons like loss to follow up
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or end of study. Particular methods may additionally assume proportional
hazards for the covariates. Note that since we do not censor at the moment
of treatment start, this strategy requires continued follow up after treatment
initiation.
4.2 “Composite” strategy
Also with this strategy the analysis is relatively straightforward and can
be done with any chosen survival regression technique. Either occurrence
of the event of interest or the occurrence of treatment counts as an event,
whichever comes first. When one would use a Cox-like model, the assumption
of proportionality of covariate effects should hold for the composite outcome,
which may be less likely than for single outcomes. Also, the non-informative
censoring by loss to follow up or end of study should hold in relation to the
composite outcome. Continued follow up after treatment initiation is not
needed.
4.3 “While untreated” strategy
Estimation of cumulative incidence as expressed in (3) can be done with
competing risks methods. Without covariates and without censoring for other
reasons like loss to follow up or end of study, cumulative incidence is estimable
by the number of patients with the event of interest divided by the total
number of patients at baseline. With covariates and censoring for reasons
like loss to follow up or end of study, the estimation can be done in various
ways, see for instance [10, 21, 22, 23, 24]. Continued follow up after treatment
initiation is not needed.
4.4 “Hypothetical” strategy
Estimation of (4) is challenging and relies on strong assumptions regarding
the treatment assignment policy in the development data. These assump-
tions are similar to those that are needed for identifying the causal treatment
effect of A, which makes sense since the strategy implicitly imposes a coun-
terfactual or potential outcome version of A into the estimand of interest.
Three key assumptions are required: exchangeability, consistency and pos-
itivity [25]. The first one, exchangeability, is often the most challenging.
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It is sometimes called the ‘no unmeasured confounding’ assumption and re-
quires that we have measured and appropriately corrected for (a sufficient
subset of) the variables that both influenced the treatment decisions and are
prognostic for the event of interest [25]. This typically requires measuring
time-dependent covariates since updated measurements of risk factors are
very likely to influence treatment decisions. The second assumption, consis-
tency, is often described as observed outcomes being equal to counterfactual
outcomes. It means that in the hypothetical world where treatment is elimi-
nated, a patient’s untreated risk is the same as her or his untreated risk in the
real world. If knowledge of the unavailability of treatment changes the risk
behaviour of patients, this assumption does not hold. This second assump-
tion is typically not prohibitive; in some causal frameworks such changing
risk behaviour is taken as a definition of the patient population [26]. The
third assumption, positivity, means that we have observed a non-zero number
of treated and untreated patients in our data for all covariate patterns during
the time horizon that we want to use in our predictions (or have observed
a sufficient number so as to smooth over gaps with modelling assumptions).
For instance if all patients with a certain characteristic are treated after 1
year, then we don’t have information for estimating untreated outcomes be-
yond one year for such patients. It may well be that a shorter prediction
horizon thor has to be chosen to fulfil the positivity assumption.
The analysis approach for the “hypothetical” strategy depends on how
treatment decisions were made for the patients in the development data and
on whether or not post-treatment follow up is used. Below, we sketch four
analysis approaches. We first discuss two settings where it is assumed that
in the development dataset treatment decisions were only based on baseline
covariates X(0), i.e., prognostic patient characteristics that are known at the
moment we want to make the prediction. In most healthcare settings it is
quite implausible that risk factor progression after baseline doesn’t influence
treatment decisions, but we include these options to indicate the limitations
of common estimation approaches. Then, we discuss two settings where risk
factor progression is accounted for. There are two analysis approaches to
target the hypothetical risk: we may stop follow up when treatment is started,
by censoring the time to event of interest at the moment treatment starts
(Figure 1a), or follow up data after the start of treatment may be included
(Figure 1b). As noted before, in some studies no follow up information is
collected after treatment initiation, in which case only the censoring option
remains. In the censoring approach positivity is only needed for untreated
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individuals, i.e., if for some covariate patterns no patients are treated, this is
not per se a problem for estimating the untreated risk.
Several other estimation approaches than the ones described below have
been proposed for the hypothetical untreated risk, each with their own as-
sumptions. For instance using g-formula [17], copulas [27, 28] or multiple
imputation [29, 30]. We refer to the mentioned references for further details
on these methods.
4.4.1 Baseline covariates, censoring
In the situation sketched in Figure 1a, time to event is censored at treatment
start. The main assumption of this approach is that censoring by treat-
ment is non-informative, conditional on the baseline prognostic covariates
in the prediction model (X(0)). In other words, censoring the follow up at
treatment start only gives a valid estimate of the hypothetical untreated risk
if baseline prognostic factors that relate to treatment are included in the
prediction model and treatment start is independent of changing values of
prognostic markers during follow-up, i.e., Ht = {X(0)}. This is a strong
and often implausible assumption that cannot be tested on the data. Such
an assumption can only be verified with those who were responsible for the
treatment decisions.
4.4.2 Baseline covariates, modelling
When follow up after treatment start is available, this follow-up information
can be used in the development of the prediction model. Treatment A can be
added as an additional, time dependent, covariate to the prediction model.
Then a prediction under the “hypothetical” strategy of no treatment can be
obtained by setting A(t) = 0 for all t in the prediction horizon (t ≤ thor). This
approach is valid under the same strong and often implausible assumption
as the first approach that we described. Only in case treatment choices were
solely based on collected prognostic baseline factors that are included in the
prediction, the model including X(0) is sufficient to get an unconfounded
estimate of the effect of A. There is a caveat to this approach of modelling
the treatment effect. The advantage of using a longer period of follow up is
at the expense of having to model the effect of the treatment on the event
of interest. Therefore, the functional form of the treatment effect should be
carefully chosen: the assumption of proportional hazards between the treated
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and untreated patients over time and the presence of possible interactions
between patient characteristics and treatment should be checked.
4.4.3 Time varying covariates, censoring
We now turn to the more realistic situation where time-varying prognostic
patient characteristics have additionally influenced the treatment decisions,
i.e., Ht = {X(s), s ≤ t}. For example when the condition of patients has
been monitored by repeatedly measuring their blood values and these mea-
surements have influenced the decisions about treatment initiation. In the
censoring case (Figure 1a), inverse probability of censoring weighting (IPCW)
could be used. This approach assumes that treatment start is independent of
the future untreated risk conditional on baseline covariates X(0) and time de-
pendent covariates X(t). X(t) is used to estimate time-varying conditional
probabilities of starting treatment. By assigning weights to patients that
are inversely proportional to their conditional probability of not yet being
treated, a weighted population is created that (under the assumptions of ex-
changeability, consistency and positivity) mirrors the pseudo-population that
would have been observed in the absence of treatment [31, 32, 33, 34, 17].
Applying inverse probability weighting when estimating a survival model for
the event of interest with censoring at treatment start thus corrects for the
informative censoring related to X(t) .
4.4.4 Time varying covariates, modelling
When post-treatment follow up is used to model the effect of treatment on
the event of interest, adding both X(t) and A in the survival model similar
to Section 4.4.2, will in the presence of time varying covariates not yield a
useful prediction model, because for a new patient X(t) will not be known
when predicting at baseline. The hypothetical untreated risk to estimate
from Figure 1b is similar to what is called the ‘controlled direct effect’ in
mediation analysis, when setting treatment as the mediator at a fixed zero
level (no treatment) [35]. A potential solution is to fit a marginal structural
model with inverse probability of treatment weighting (IPTW) to break the
link between X(t) and A(t) [36]. Using these weights, a model containing
X(0), A(t) and potential interactions as predictors can be fitted and one can
estimate the hypothetical risk from this model setting A(t) = 0. Details
on implementing this approach for prediction modelling in both logistic and
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time-to-event models can be found in [3]. We again have to assume correct
specification of the treatment effect.
5 Data application
In this section, we study the four proposed prediction estimands in data from
the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)
[37]. This study is a multicenter cohort study in which patients with end
stage renal disease were included at dialysis initiation if they were 18 years
or older and had no previous kidney transplantation and no previous dialysis.
The NECOSAD study was approved by the local medical ethics committees
and all patients gave informed consent. Patients were followed until renal
transplantation, death or end of study. Here we consider death the event
of interest and renal transplantation is the treatment that may be initiated
at some point in time after baseline. As in NECOSAD patients were not
followed after renal transplantation, information on death after transplan-
tation was retrieved by linking the NECOSAD data to the Dutch registry
of renal replacement therapy, RENINE (Registratie Nierfunctievervanging
Nederland) [38]. Patients were included between 1997 and 2007, and fol-
lowed until February 1, 2015. Patients who were not coded as deceased or
lost to follow up in RENINE were assumed to be alive at end of follow up.
Our initial data set contained n=2051 patients. We removed 6 patients with
missing information on age, yielding 2045 patients in our analysis. For 43
patients who were still alive at the last follow up visit of the NECOSAD
study, no link to the registry could be made and we censored time to death
and, where applicable, time to transplantation for these patients at their last
follow up in NECOSAD. The median time in follow up of the 2045 patients
was 5.1 years. In this period, 749 patients received a kidney transplant, 1470
patients died of whom 248 after transplantation. Age and baseline dialy-
sis type (hemodialysis (HD) versus peritoneal dialysis (PD)) were used as
baseline predictors of mortality (X(0)). With HD, blood is pumped out of
the patient’s body and filtered by an artificial kidney machine. With PD,
cleansing fluid is pumped into the patient’s abdominal cavity and the lin-
ing of the abdomen acts as a natural filter to wash out waste and toxins.
As this example is used for illustration purpose, we did not include more
baseline variables in the prediction model. Additionally, for estimating the
hypothetical prediction estimand, we used the following time dependent co-
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variates X(t) as predictors of treatment: Charlson comorbidity score, BMI
and calcium blood values, which were measured at 6 months intervals. We
estimated the mortality risk over a time span of 10 years, given age (as a con-
tinuous variable) and baseline dialysis type. We used the packages survival,
mstate, and ipw of the R statistical software [39]. Our analysis code along
with a simulated dataset can be found in the Supplementary Materials. The
different predictimands were estimated as follows:
• The “ignore treatment” strategy targets the total mortality risk, re-
gardless of whether patients did or did not receive a transplantation.
For estimation, we used a Cox proportional hazards model with the
non-parametric baseline hazard estimated using the approach proposed
by Efron (further on referred to as Cox-Efron) [40]. Death was defined
as the event, age and dialysis type as baseline covariates and we cen-
sored the patients alive at the moment of last follow up. Note that for
estimating the “ignore treatment” risk, follow up for death after trans-
plantation is needed, which was retrieved by linking the NECOSAD
data to the Dutch Renal Registry.
• With the “composite” strategy, we estimate the risk of either dying
or receiving a transplantation. To this end, transplantation and death
were combined as composite event in a Cox-Efron analysis, again with
age and dialysis type as baseline covariates and censoring those alive
at the moment of last follow up. Studying a composite outcome in this
situation can be informative, e.g., for policy makers, to know how long
patients will likely stay alive and without transplantation and thus
remain on dialysis treatment. For estimating the “composite” risk,
follow up after transplantation is not needed.
• The “while untreated” strategy assesses the risk of dying before re-
ceiving a transplantation. To estimate this risk, we fitted two cause-
specific Cox-Efron models: one model with death as event, age and
dialysis type as baseline covariates and censoring at time of transplant
or at moment of last follow up alive, and one model with transplant
as event, age and dialysis type as baseline covariates and censoring at
death and at last follow up alive. The two cause specific hazard models
were used to obtain the cumulative incidence for death [10]. Follow up
after transplantation is not needed for the “while untreated” risk.
16
• In the “hypothetical” strategy we estimate the risk of dying if no trans-
plantation is performed. We followed the four different estimation
methods described in Section 4.4.
– First, we fitted a Cox-Efron model for death, with age and dialysis
type as baseline covariates and where event times were censored
when the patient received a transplantation or at the end of follow
up. This model was then used to predict the mortality risk over
time. This approach assumes that the decisions on transplantation
were based only on on age and dialysis type. Follow up after
transplantation is not needed in this case.
– Second, transplantation was included as a time-dependent covari-
ate in a Cox-Efron model with age and dialysis type as baseline
covariates, again assuming that only these two baseline covariates
drove the transplantation decisions. To model the effect of trans-
plantation correctly, we explored whether adding interactions be-
tween transplantation and baseline covariates improved the model,
but it did not. Since the transplantation effect seemed to change
over time, we used a time varying coefficient for treatment accord-
ing to a step function (with jumps at 3 and 8 years, chosen by vi-
sual inspection of the Schoenfeld residual plot). The hypothetical
untreated risk was then estimated by setting A(t) = 0. For this
second approach where the effect of transplantation is modelled,
we needed the additional follow up of death after transplantation.
– Third, we repeated the first analysis where we censored at treat-
ment start, now applying inverse probability weighting to cor-
rect for time-dependent covariates that might have additionally
influenced the transplantation decisions. Stabilized weights were
estimated based on two Cox-Efron models with transplantation
as event: a denominator model including Charlson comorbidity
score, BMI and calcium blood values as covariates and a numera-
tor model with only an intercept. Some missings occurred in the
time dependent covariates and we performed a single imputation
method for each using a linear mixed model with follow up time,
age and dialysis type as fixed factors and a random intercept. For
patients who did not have any measurement of these covariates (1
for Charlson score, 17 for BMI, 83 for calcium), we imputed the
median of the other patients.
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– Fourth, we repeated the second analysis where we modelled the
effect of transplantation, applying the same inverse probability
weights as in the third approach.
In Figure 2 the predicted 10 year mortality curves are presented for a
patient of age 50 and for a patient of age 70, both starting on hemodialysis.
Each curve represents a different type of mortality risk. Several observations
can be made from the curves. The risks obtained from the “composite” strat-
egy are highest while the curves from the “while untreated” strategy were
lowest for most of the follow up times. This is according to expectation as the
“composite” strategy counts every transplanted patient as event, while the
“while untreated” counts transplantation as non-event. The other two strate-
gies infer that part of the transplanted patients will reach the event, either
according to observed deaths after transplantation in the “ignore treatment”
strategy, or according to what would be expected if these patients were not
transplanted in the “hypothetical strategy”. The fact that the “while un-
treated” strategy does not yield the lowest predictions at all times can be
explained by the modelling assumptions (proportionality of covariates is act-
ing on different scales, composite hazard versus cause specific hazard versus
marginal hazard). The composite curves for 50 and 70 years-old were very
similar because younger patients have a lower probability of dying but a
higher probability of getting a transplantation. The four curves belonging
to the “hypothetical” strategy are higher than those from the “ignore treat-
ment” strategy, indicating that the current transplantation policy reduces
mortality compared to a hypothetical scenario where nobody would receive
a transplant. This is more apparent at age 50, since more patients are trans-
planted at that age. The curves for patients starting on peritoneal dialysis
were very similar to the curves for hemodialysis and are therefore not shown.
Our focus is on the interpretation of the different prediction estimands.
Below we sketch how our results could be used in a fictitious conversation
between a doctor and a patient of age 50 starting on hemodialysis.
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Figure 2: Predicted mortality curves and 10 year mortality risks for pa-
tients aged 50 and 70 on hemodialysis. red: composite, green: while un-
treated/cumulative incidence, black: ignore treatment, solid blue: hypothet-
ical - censor at treatment, dashed blue: hypothetical - modelling treatment,
dotted blue: hypothetical - censor at treatment + IPW, dotdash blue: hy-
pothetical - modelling treatment + IPW19
• doctor: You have progressed to end stage renal disease, meaning your
kidneys no longer function sufficiently. My advice would be to start
hemodialysis.
• patient: What is my prognosis on hemodialysis?
• doctor: If we did not perform kidney transplantations, our best esti-
mate is that 59 to 62% of patients your age would die within 10 years.
(hypothetical)
• patient: Ok, but what about my prognosis given that I may receive a
kidney transplantation?
• doctor: With availability and allocation of transplants like in recent
years, about 43% of patients dies within 10 years. (ignore treatment)
• patient: So, will I get a transplant in time?
• doctor: I cannot say, we need a matching donor and there is a waiting
list. Again assuming that availability and allocation of transplants does
not change, in the next 10 years, you have about 34% chance of dying
before getting a transplant. (while untreated)
• patient: What are the chances I will survive for 10 years and still be
on dialysis?
• doctor: With unchanged transplant availability and allocation, you
have a 5% chance to still be alive and without transplant in 10 years.
(1 minus composite)
We note that our simplified model with only two predictors is not meant
for use in clinical practice. Also for simplicity, we omitted to report uncer-
tainty intervals around the predictions. This example serves as an illustration
that the different strategies of handling treatment start after baseline answer
different risk questions.
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6 Discussion
Starting treatment after baseline is very common in risk prediction settings.
We argue that the way treatment is dealt with should not be degraded to
‘just a technical analysis choice’. In fact, different strategies may yield very
different risk predictions. If not dealt with up-front, the choice may sneak
in by the choice of analysis rather than being identified intentionally as the
prediction estimand of interest. Decisions about how one wants to handle
treatment initiation should be prespecified, based on which interpretation of
risk is most appropriate. In some cases, multiple questions may be of interest
and therefore investigators may choose to estimate more than one of the four
predictimands we described here.
Being clear about the prediction question of interest in the context of
post-baseline occurrences is not only important for treatment initiation. Any
post-baseline behaviour or event that may be modifiable could be considered
in light of our proposed framework. For example, in the transplantation
setting, another modifiable post-baseline event that could be considered is
patients who stop dialysis due to recovery. (In our analyses patients were
censored in case of ceasing dialysis due to recovery, implying we used the
“hypothetical” strategy with respect to this event.)
A recent systematic review on prediction models for on-dialysis mortal-
ity identified 16 models studying time to death [37]. Five of these used the
Cox model with censoring at transplantation, implicitly targeting the “hy-
pothetical” prediction estimand. None of these five studies explained the
consequences of censoring on treatment start for the interpretation of the
calculated risk, and none paid attention to the non-informative censoring as-
sumption. Three other models included death after transplantation in their
outcome (“ignore treatment” strategy). Three studies excluded patients who
received transplants after baseline from their analyses, leading to predictions
that are not generalizable. Five did not write anything about how they
dealt with transplantation, essentially rendering risk numbers that cannot
be interpreted.
Whereas causal inference research is typically strictly distinguished from
prediction research [41], we show in our paper that when predicting in the
presence of modifiable events after baseline such as treatment initiation,
methods from both domains are needed. A causal inference model aims
to quantify what the counterfactual or potential outcomes of patients would
be with and without an intervention and infers a causal effect of intervention
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from that. A prediction model aims to provide correct predictions of an out-
come given a set of prognostic factors that do not have to be causally related
to the outcome. The “hypothetical” prediction estimand could be classified
as a type of counterfactual prediction, since we predict potential outcomes
‘if the world were different’, namely, if no one receives treatment [41]. Sev-
eral untestable assumptions are needed here, as described in Section 4.4.
The other three prediction estimands give ‘real world’ predictions and can
be estimated from a development dataset without untestable assumptions.
However, when predicting for new patients using these three strategies, we
assume that similar treatment assignment policies apply as in the develop-
ment cohort. This is also a very strong assumption that cannot be tested
upfront. The prognostic factors used in a clinical prediction model do not
have to be causally related to the outcome, however the predictions they
render will only be valid if the treatment policies that patients to whom the
prediction model is applied are 1) clearly defined in the prediction estimand
and 2) similar as in the development cohort (except for the “hypothetical”
strategy).
Our focus in this paper is on the role of treatment in clinical prediction
models. We have sketched how different strategies of handling treatment
lead to different prediction estimands. The definition of the role of treat-
ment and other intercurrent events is necessary but not sufficient to define
a prediction estimand. Other aspects that need to be defined are the target
population/setting (e.g., patients with end stage renal disease), the relevant
outcome with an appropriate time horizon (e.g, 10-year mortality) and a
time-point at which the prediction will be made (e.g., at start of dialysis)
[42].
Throughout the paper we have referred to a single treatment and assumed
that treated patients remained treated throughout follow up. Usually many
types of treatment are relevant for patients. For instance, data used for the
development of a cardiovascular risk model may contain information on pa-
tients who start using statins, patients who start using antihypertensives or
lipid lowering drugs, patients following a particular diet etc. Depending on
the goal of the risk prediction, a choice should be made as to how each is
handled. Typically a mixture of approaches will be used. Many treatments
will be considered ‘care as usual’ with assignment policies that are considered
stable over time and can be handled as background according to the ‘ignore
treatment’ strategy. However, if for example the prediction model is aimed to
input to the question of whether new patients should or should not be given
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statins, then a different strategy should be used for statins. For each treat-
ment, an explicit choice should be made as to which prediction estimand is
targeted and appropriate attention should be given to the necessary assump-
tions for estimating this. When only few patients are treated (e.g., due to a
short prediction horizon) or when treatment effects are small relative to the
effect of the other prognostic factors in the model, the numerical differences
between the strategies will be less pronounced than in our transplantation
example, but may still be relevant.
In case patients switch between ‘off’ and ‘on’ treatment multiple times
during follow up, the definition and analysis approach of the “ignore treat-
ment” and “hypothetical” strategy can stay unchanged. An application of
the “hypothetical” strategy in such an ‘on’ and ‘off’ switching situation is
presented in [9]. In the “composite” strategy it seems most sensible to count
the first occurrence of a treatment episode as an event, but recurrent event
approaches could also be considered [43]. The definition of the “while un-
treated” strategy could be extended to represent the risk of the event of
interest during all untreated episodes, so not only up to the first treatment
episode as in the current definition.
An aspect of prediction modelling that was not addressed in our paper
is assessment of predictive performance, i.e., model validation. Standard
methods to validation of predictions apply to the “ignore treatment” and
“composite” predictimands. For the “while untreated” strategy, methods
suitable for competing risks analyses are needed, see for instance [44, 45,
46]. Validating predictions generated with the “hypothetical” strategy is
more involved since also in a validation dataset there will likely be patients
who start treatment after baseline. Validation in such a setting may require
similar assumptions and estimation techniques as during estimation of the
hypothetical predictions [47]. This warrants further research.
There might be a trade-off between relevance of an estimand and the
assumptions that one is willing to make in order to produce it. Due to
its strong and untestable assumptions some authors have argued against
using a “hypothetical” estimand saying one can better ‘stick to this world’
[48]. We argue that the future use of the prediction model should drive the
predictimand choice. One should start by defining a clear estimand before
considering how to compute it. When there is much uncertainty on the used
assumptions, sensitivity analyses could be performed to assess the degree of
uncertainty in the predictions [49].
In any case, when using a prediction model in clinical care, the meaning
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of predictions presented to patients should be unequivocally clear. Our pre-
dictimand framework can help researchers explicating what risk is targeted
by their model.
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